Close this search box.

AIIMS Delhi to commence human trials of Covaxin from today

AIIMS Delhi to commence human trials of Covaxin from today
The All India Institute of Medical Sciences (AIIMS) Ethics Committee on Saturday gave its authorization for the human clinical trial of Covaxin, a coronavirus vaccine candidate.

From today on, the hospital will continue to enroll healthier individuals, news agency PTI announced.AIIMS-Delhi is one of the 12 sites chosen by the Indian Council for Medical Research (ICMR) for Phase I and Phase II human Covaxin trials. In Phase I, the vaccine will be tested on 375 volunteers and a limit of 100 would be AIIMS.

Volunteers are needed for the Covid-19 Vaccine clinical trial at AIIMS Delhi. Healthy patients with no comorbid conditions and with no record of COVID-19, over 18 years of age and under 55 years of age, will be eligible to enroll in a randomized, double-blind, placebo-controlled clinical trial.

India’s first indigenous Covid-19 vaccine candidate Covaxin is being developed by Hyderabad-based Bharat Biotech in cooperation with the ICMR and the National Institute of Virology (NIV).



Copyright 2023 © Insightscare Magazine ( a Digital Ink brand ) All rights reserved.